ArteraAI Announces First-Ever AI-Derived Biomarker for Predicting Androgen Deprivation Therapy (ADT) Benefit in Prostate Cancer

Data published in the NEJM Evidence shows promise for personalized use of short-term ADT in men with predominantly intermediate-risk prostate cancer

Excerpt from the Press Release:

SAN FRANCISCO–(BUSINESS WIRE)–ArteraAI, the developer of multimodal artificial intelligence-based predictive and prognostic cancer tests, announced today the publication of data in the NEJM Evidence, validating the first-ever predictive AI biomarker of androgen deprivation therapy (ADT) benefit in prostate cancer.

The study used novel deep learning methodology and histopathology image data from more than 5,000 patients across five Phase 3 randomized trials, with long-term follow-up. Patients in these trials were enrolled from over 100 centers across the US and Canada. The predictive AI biomarker was developed using datasets comprising about 20% African American patients. In past U.S.-based clinical trials, African American men have made up only 10.8% of prostate cancer trial participants.

“This is truly a milestone in the treatment for prostate cancer,” said Dr. Daniel Spratt, MD, chairman and professor of radiation oncology at University Hospitals (UH) Seidman Cancer Center and Case Western Reserve University (CWRU), and one of the corresponding authors on the study. “With the first-ever predictive biomarker of ADT benefit in prostate cancer, created with AI, we are able to further realize the ability to create a personalized approach for the treatment of cancer.”

In patients with localized prostate cancer, ADT can be added to radiotherapy if improved patient outcomes are anticipated. However, ADT is also known to have negative side effects ranging from loss of sexual function to potentially detrimental effects on cardiac and brain health.

Click the button below to read the entire Press Release:

Continue Reading The Press Release